Cyberdyne
VC Fund
Tsukuba, Japan
Cyberdyne is a VC fund in Tsukuba focused on Health Care and Medical. CYBERDYNE Inc. is a venture firm which is established by Dr. Yoshiyuki Sankai, University of Tsukuba, Japan, in order to materialize his idea to utilize Robot Suit HAL® for the benefits of humankind in the field of medicine, caregiving, welfare, labor, heavy works, entertainment and so on. Robot Suit HAL® was developed with the technologies createdin Sankai Laboratory of Tsukuba University as an application of “Cybernics*” advocated by Prof. Sankai.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Cyberdyne invests in
Stages Cyberdyne invests in
Countries Cyberdyne invests in
Round sizes
Round size
- Seed
- $1.4M–$50M
- Series B
- $6.4M–$213M
Investment Focus
Industry
- Health Care 9 (36%)
- Medical 8 (32%)
- Manufacturing 6 (24%)
- Information Technology 6 (24%)
- Software 5 (20%)
Stage
- Series B 6 (24%)
- Seed 4 (16%)
- Corporate Round 4 (16%)
- Series A 3 (12%)
- Funding Round 3 (12%)
Country
- Japan 21 (84%)
- United States 2 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hirosaki Lifescience Innovation
|
Hirosaki Lifescience Innovation is engaged in the development, manufacture, and sale of regenerative medicine products. | $15.2M / Series C / Jul 22, 2024 | |
Metcela
|
Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies.Metcela's therapy uses a specific fibroblast cell that is obtained from the patient's heart and instead of replacing them, it repairs the damage by enhancing the cells' ability to heal, providing patients with an effective and reasonably-priced cure for heart failure.It was founded on March 9, 2016, and is headquartered in Kawasaki, Japan. | $13.7M / Series C / Jun 28, 2022 | |
LIFESCAPES
|
LIFESCAPES is a research and manufacturer of brain-computer interface equipment. | $5.3M / Seed / Jun 20, 2022 | |
KanonCure
|
KanonCure is a research and development company that engages in the discovery and development of regenerative medicine products and pharmaceuticals for liver diseases. The company conducts research in cell therapy and related therapeutic approaches for the treatment, diagnosis, and prevention of severe liver disorders. Its work includes methodsintended to reduce fibrosis associated with cirrhosis and support liver tissue regeneration. | $4.6M / Venture - Series Unknown / Aug 05, 2021 | |
Rehab
|
Rehab develops a rehabilitation support SaaS "Rehaplan" for adult day care centers. | $6.4M / Series B / May 24, 2021 | |
Allm
|
Allm is a medical ICT company dedicated to shaping healthcare. The company seeks to benefit society by launching next-generation technologies and medical communications platforms for the healthcare industry. The solutions are installed more than 18 countries across US, South America, EU, Japan, Middle East and Africa. | $50.8M / Series A / Apr 05, 2021 | |
Jiksak Bioengineering
|
Jiksak Bioengineering is a biotechnology company. Jiksak Bioengineering provide an efficient screening service using a three-dimensional cell tissue "Nerve Organoid". We will mainly develop screening technologies specifically for neurodegenerative diseases and search for drugs that are effective for amyotrophic lateral sclerosis (ALS). | Series B / Mar 23, 2021 | |
World Life Mapping
|
World Life Mapping is an Information technology company that develops mental health cares system services for psychological wellness. | Seed / Feb 22, 2021 | |
ANSeen
|
ANSeeN implemented a third-party allotment of new shares underwritten by real tech fund. | $8.5M / Series B / Sep 07, 2020 | |
Aillis
|
Aillis specializes in the development of testing methods for Influenza using artificial intelligence technology. The company mainly focuses on new methods of diagnosing influenza. The company was founded in 2017. | Series B / Aug 06, 2020 | |
| See all 25 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Cyberdyne invest in?
Cyberdyne invests primarily in Health Care, Medical and Manufacturing startups, most often at Series B and Seed stage. Most of the 25 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Cyberdyne's check size?
Cyberdyne typically joins rounds of $1.4M–$50M at Seed and $6.4M–$213M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cyberdyne participates in.
When did Cyberdyne last invest?
The most recent investment recorded for Cyberdyne closed in Jul 2024. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
